HepaRG^™ Cells AHR (-/-)

HepaRG is a human hepatoma cell line. The cells possess a pseudodiploid karyotype and have been characterized as an oval ductular bipotent hepatic cell line as they have the ability to differentiate into both biliary and hepatocyte lineages in the presence of DMSO. HepaRG AHR knockout cells express the major xenobiotic sensors (PXR and CAR), drug transporters, phase I and II drug metabolizing enzymes as well as key hepatic transcription factors involved in stress response pathways.

See technical bulletin for detailed protocols

HepaRG cells are the most metabolically active human hepatocyte cell line developed to date. These the cells are suitable for a wide variety of studies for drug metabolism, CYP induction, metabolism-mediated toxicity, transporter, and hepatotoxicity. - Sigma′s HepaRG AHR Knockout (KO) allows conclusive identification of CYP1A1 and CYP1B1 induction through AHR activation.

Zinc finger nucleases (ZFN) mediated Knockout of AHR (AHR) gene.

• The frame-shift mutation of AHR gene was confirmed by fragment length analysis and DNA sequencing.
• Loss of functionality was confirmed by loss of response to inducers of cytochrome P450 activity.

Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation.

Exhibit 1: ADME/Tox cell lines license
Exhibit 2: HepaRG limited use license

HepaRG is a trademark of BioPredic International company

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.